---
title: "DENALI CAPITAL ACQUISITION CORP C/WTS 28/03/2027(TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.15"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/253211177.md"
published_at: "2025-08-15T11:51:41.000Z"
---

# DENALI CAPITAL ACQUISITION CORP C/WTS 28/03/2027(TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -0.15

EPS: As of FY2025 Q2, the actual value is USD -0.15.

### Segment Revenue

-   **Formation and Operating Costs**: For the three months ended June 30, 2025, formation and operating costs were $374,857, compared to $168,186 for the same period in 2024. For the six months ended June 30, 2025, these costs were $621,457, compared to $536,438 for the same period in 2024.

### Operational Metrics

-   **Net Income/Loss**: For the three months ended June 30, 2025, the net loss was - $385,122, compared to a net income of $448,912 for the same period in 2024. For the six months ended June 30, 2025, the net loss was - $579,725, compared to a net income of $713,242 for the same period in 2024.
-   **Interest Expense**: For the three months ended June 30, 2025, interest expense was $28,345, compared to $23,059 for the same period in 2024. For the six months ended June 30, 2025, interest expense was $55,319, compared to $44,362 for the same period in 2024.

### Cash Flow

-   **Operating Cash Flow**: For the six months ended June 30, 2025, net cash used in operating activities was - $183,512, compared to - $488,664 for the same period in 2024.
-   **Investing Cash Flow**: For the six months ended June 30, 2025, net cash provided by investing activities was $8,617,553, primarily due to cash withdrawn from the trust account in connection with the redemption of ordinary shares.
-   **Financing Cash Flow**: For the six months ended June 30, 2025, net cash used in financing activities was - $8,450,783, primarily due to cash paid for the redemption of ordinary shares amounting to $8,617,553, offset by the proceeds from the issuance of a promissory note to a related party of $166,770.

### Future Outlook and Strategy

-   **Core Business Focus**: The company is focused on completing its initial business combination with Semnur Pharmaceuticals, Inc. The merger agreement includes a total consideration of $2,500,000,000 payable in New Semnur Common Shares, with the merger expected to close by September 30, 2025, subject to further extension if necessary.
-   **Non-Core Business**: The company has entered into various agreements to support the merger, including a Sponsor Support Agreement and a Stockholder Support Agreement, to ensure the successful completion of the business combination with Semnur Pharmaceuticals, Inc.

### Related Stocks

- [DNQWF.US - DENALI CAPITAL ACQUISITION CORP C/WTS 28/03/2027(TO PUR COM)](https://longbridge.com/en/quote/DNQWF.US.md)
- [SMNRW.US - SEMNUR PHARMACEUTICALS INC C/WTS 22/09/2030(TO PUR COM)REV SPLT](https://longbridge.com/en/quote/SMNRW.US.md)

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.